DRD2 and Parkinson disease: Dopamine agonists have been consistently responsible for behavioral issues and disorders of sleep in PD, to a much greater extent that levo-dopa, suggesting that targeting of specific dopamine receptors, most likely the dopamine D2 receptor, might be causative.